

FDA 510(k), Premarket Notification : 510(k) Summary of Safety and Effectiveness Information**1.0 Submitter:**

WEAR SAFE (MALAYSIA) SDN. BHD.
Lot PT 13726, Jalan Haji Salleh, Off Jalan Meru, 41050 Klang,
Selangor Darul Eshan,
Malaysia.

Telephone No.: +603 3392 3088
Fax No.: +603 3392 2118

2.0 Contact Person:

Contact: Mr. SH TAN
E-mail: shtan@kossan.com.my
Telephone No.: +603 3291 2657
Fax No.: +603 3291 0584

3.0 Name of Device:

Trade Name: Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored), Non-Sterile (Chemotherapy Drug Protection Labeling Claim)
Common Name: Patient Examination Glove
Classification Name: Patient Examination Glove.

4.0 Identification of The Legally Marketed Device:

The Powder Free Nitrile Examination Gloves, White (non colored) or Blue (colored), Non-Sterile (Chemotherapy Drug Protection Labeling Claim), Class I Patient Examination gloves, 80LZC, meets all of the requirements of ASTM D6319 Standard Specification for Nitrile Examination Gloves for Medical Application.

5.0 Description of Device:

Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored), Non Sterile (Chemotherapy Drug Protection Labeling Claim) will meet all the current specification for ASTM D6319.

K093500

6.0 Intended Use of the Device:

Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored), Non Sterile (Chemotherapy Drug Protection Labeling Claim) is a disposable device intended for medical purposes that is intended to be worn on the hand for medical purposes to provide barrier against potentially infectious materials and other contaminants. In addition, this product is tested for use with chemotherapy drugs.

7.0 Summary of The Technological Characteristics of The Device:

Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored), Non Sterile (Chemotherapy Drug Protection Labeling Claim) possesses the following technological characteristic (as compared to ASTM or equivalent standards):

Characteristic	Standards	Device Performance
Dimensions	ASTM D6319 – 00a(2005)e1	Meets
Physical Properties	ASTM D 412 – 06ae1	Meets
Freedom from pin-holes	ASTM D 5151 - 06	Meets
Powder Free Residue	ASTM D 6124 - 06	Meets
Biocompatibility	Dermal Sensitization (as per ASTM F720-81)	Not a contact skin sensitizer
	Primary Skin Irritation Test (as per 16CFR Part1500)	Not a primary skin irritant

8.0 Substantial Equivalent Based on Assessment of Non-Clinical Performance Data

The performance test data that support a determination of substantial equivalence are described above.

9.0 Substantial Equivalent Based on Assessment of Clinical Performance Data

Clinical data are not needed for market cleared examination gloves.

10.0 Conclusion

It can be concluded that the Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored) or, Non Sterile (Chemotherapy Drug Protection Labeling Claim) is safe and effective for use and will perform according to the glove performance standards referenced in Section 7 above, thereby meeting ASTM standards, FDA requirements, and the labeling claims for the product.

Consequently, this device is substantially equivalent to current marketed devices.

This summary will include any other information reasonably deemed necessary by the FDA.



JAN 19 2010

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room W-O66-0609
Silver Spring, MD 20993-0002

Mr. S.H. Tan
Regulatory Affairs Department Manager
Wear Safe MALAYSIA Sdn. Bhd.
Lot PT 13726, Jalan Haji Salleh off Jalan Meru
Klang Selangor Darul Ehsan
MALAYSIA 41050

Re: K093500

Trade/Device Name: Powder Free Nitrile Examination Gloves, White (non-colored) or
Bule (colored), Non-Sterile (Chemotherapy Drug Protection Labeling Claim)
Regulation Number: 21CFR 880.6250
Regulation Name: Patient Examination Glove
Regulatory Class: I
Product Code: LZC
Dated: December 23, 2009
Received: December 29, 2009

Dear Mr. Tan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to


<http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Anthony D. Watson, BS, MS, MBA
Director

Division of Anesthesiology, General Hospital,
Infection Control, and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

Applicant: WEAR SAFE (MALAYSIA) SDN. BHD.

510(k) Number (if known): K093500

Device Name: Powder Free Nitrile Examination Gloves, White (non-colored) or Blue (colored), Non-Sterile (Chemotherapy Drug Protection Labeling Claim)

Indication For Use: A powder free nitrile examination glove is a disposable device made of synthetic material intended to be worn on the hand for medical purposes to provide barrier against potentially infectious materials and other contaminants. In addition, this product is tested for use with chemotherapy drugs.

Powder Free Nitrile Patient Examination Gloves, White (Non-Colored) Non Sterile (Chemotherapy Drugs Protection Claim): <i>Chemotherapy Drug Permeation (Breakthrough Detection Time) in Minutes</i> <i>The following chemotherapy drugs have been tested:</i>	
Carmustine (BCNU) (3.3mg/ml)	71.3
Cisplatin (1.0 mg/ml)	>240
Cyclophosphamide (Cytoxan) (20.0 mg/ml)	>240
Dacarbazine (DTIC) (10.0 mg/ml)	>240
Doxorubicin Hydrochloride (2.0 mg/ml)	>240
5-Fluorouracil (50.0 mg/ml)	>240
Etoposide (Toposar) (20.0 mg/ml)	>240
Paclitaxel (Taxol) (6.0 mg/ml)	>240
ThioTepa (10.0 mg/ml)	72.36

Powder Free Nitrile Patient Examination Gloves, Blue (Colored) Non sterile (Chemotherapy Drugs Protection Claim): <i>Chemotherapy Drug Permeation (Breakthrough Detection Time) in Minutes</i> <i>The following chemotherapy drugs have been tested:</i>	
Carmustine (BCNU) (3.3mg/ml)	60.7
Cisplatin (1.0 mg/ml)	>240
Cyclophosphamide (Cytoxan) (20.0 mg/ml)	>240
Dacarbazine (DTIC) (10.0 mg/ml)	>240
Doxorubicin Hydrochloride (2.0 mg/ml)	>240
5-Fluorouracil (50.0 mg/ml)	>240
Etoposide (Toposar) (20.0 mg/ml)	>240
Paclitaxel (Taxol) (6.0 mg/ml)	>240
ThioTepa (10.0 mg/ml)	69.0

K093500

WSM Wear Safe (Malaysia) Sdn.Bhd. (Company No.204396-X)


revised copy

Prescription Use _____
(Part 21 CFR 801 Subpart D)

AND/OR Over-The-Counter Use X
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


Elizabeth P. Clavner Wall

(Division Sign-Off)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K 0 9 3 5 0 0

Page 2 of 2